Live
- Bihar: Deceased patient's eye missing, RJD condemns incident at Nalanda Medical College
- Rammurthy Naidu's Last Rites Held in Naravari Palli
- PM Modi receives ceremonial welcome in Abuja, begins bilateral talks with Nigerian President Tinubu
- Goods traffic doubles on the new railway freight corridors
- BGT 2024-25: I’d like to see him make one more Test ton in Australia, says Johnso
- Harassment due to ED raids forced Kailash Gehlot to quit, hints Kejriwal
- Kailash Gehlot exit: BJP goes on the offensive against 'corrupt' AAP govt
- PM Modi pays homage to ‘the great’ Balasaheb Thackeray on his death anniversary
- One who cares for Delhi will not stay with gang of robbers: Sachdeva on Gahlot's resignation
- From Self-Doubt to Self-Love: Vange Cain’s Inspirational Path
Centre enters into Rs 30-crore Covid vax deal with Biological-E
Centre enters into Rs 30-crore Covid vax deal with Biological-E
The Union Health Ministry has finalised arrangements with Hyderabad-based vaccine manufacturer Biological-E to reserve 30 crore Covid-19 vaccine doses for which it will be making an advance payment of Rs 1,500 crore
New Delhi: The Union Health Ministry has finalised arrangements with Hyderabad-based vaccine manufacturer Biological-E to reserve 30 crore Covid-19 vaccine doses for which it will be making an advance payment of Rs 1,500 crore.
These vaccine doses will be manufactured and stockpiled by Biological-E from August to December this year, a ministry statement said on Thursday. The Covid-19 vaccine of Biological-E is currently undergoing phase-3 clinical trial after showing promising results in phase 1 and 2 trials.
The vaccine being developed by Biological-E is a RBD protein sub-unit vaccine and is likely to be available in the next few months.
The proposal of Biological-E was examined and recommended for approval after due diligence by the National Expert Group on Vaccine Administration for Covid-19 (NEGVAC), the statement said. The arrangement with Biological-E is part of the wider endeavour of the Centre to encourage indigenous vaccine manufacturers by providing them support in research and development and also financial support, it said.
The Biological-E Covid vaccine candidate has been supported by the Centre from preclinical stage to phase-3 studies.
The Department of Biotechnology has not only provided financial assistance in terms of grant-in-aid of over Rs 100 crore but has also partnered with Biological-E to conduct all animal challenge and assay studies through its Research Institute Translational Health Science Technology Institute (THSTI), Faridabad.
